🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Metabolomic Profile of Vitreoretinal Diseases: an NMR-Based Approach Using Vitreous.

Recruitingn/aAges 40 Years - 90 YearsAllRenmin Hospital of Wuhan University
NCT06429969 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The goal of this observational study was to learn about metabolomics profiles in vitreoretinal diseases by nuclear magnetic resonance (NMR)using vitreous fluid. The main question it aimed to answer was abnormal biomarkers for common retinal diseases such as idiopathic macular hole(IMH), diabetic retinopathy(DR) and retinal detachment(RD). Participants would not be subjected to any intervention and the investigators would only collect preoperative information and remaining vitreous samples. The investigators divided the participants into groups with appropriate disease names based on the disease diagnosis, such as IMH group, DR group, and RD group. The MH group was used as a control group, investigators compared other groups to see the metabolomic abnormalities.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Confirmation of IMH diagnosis with concomitant need for PPV surgery; 2. Confirmation of DR diagnosis with concomitant need for PPV surgery; 3. Confirmation of RD diagnosis with concomitant need for PPV surgery; 4. Confirmation of IMM diagnosis with concomitant need for PPV surgery; 5. Confirmation of RVO diagnosis with concomitant need for PPV surgery. Exclusion Criteria: 1. Diagnosed vitreoretinal disease with no need for PPV surgery; 2. Previous history of PPV surgery; 3. Combination of other active ophthalmic diseases, such as acute conjunctivitis and uveitis; 4. Combination of serious systemic diseases such as hypertension and diabetes mellitus.
💊

What it tests

  • Not listed
📍

Where

1 site
Eye, Center, Renmin Hospital of Wuhan University
Wuhan, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy